Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward (Q37959165)

25 August 2017

title

Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward (English)

1 reference

25 August 2017

1 reference

Samuel S Blumenthal

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 November 2011

1 reference

25 August 2017

published in

Postgraduate Medicine

1 reference

25 August 2017

volume

123

1 reference

25 August 2017

issue

6

1 reference

25 August 2017

page(s)

166-179

1 reference

The prevention or delay of type 2 diabetes

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Renal and retinal effects of enalapril and losartan in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Standards of medical care in diabetes--2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Predictors of hyperkalemia risk following hypertension control with aldosterone blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Potential new therapeutic agents for diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Structural-functional relationships in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Hypertension, transforming growth factor-beta, angiotensin II and kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Association between transforming growth factor-beta and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Combined paracrine and endocrine AAV9 mediated expression of hepatocyte growth factor for the treatment of renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Profiling of anti-fibrotic signaling by hepatocyte growth factor in renal fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Endogenous hepatocyte growth factor attenuates inflammatory response in glycerol-induced acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Elevated hepatocyte growth factor in sera from patients with insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Oxidative stress and diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Renal catabolism of advanced glycation end products: the fate of pentosidine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Differential accumulation of advanced glycation end products in the course of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Pyridoxamine: the many virtues of a maillard reaction inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.11.2506

21 January 2018

Identifiers

DOI

10.3810/PGM.2011.11.2506

1 reference

25 August 2017

1 reference